Enveda's ENV-294 Shows 85% EASI Reduction in Phase 1b Atopic Dermatitis Trial
Key Insights
Enveda (search)'s first-in-class oral therapy ENV-294 demonstrated an 85% mean reduction in EASI scores by Day 42 in a Phase 1b trial of nine patients with moderate-to-severe atopic dermatitis (search).
All patients achieved EASI-50 response, with 78% reaching EASI-75 and 56% achieving EASI-90, including two patients with complete skin clearance by Day 42.
The novel "LOCKTAC" mechanism showed favorable safety with no serious adverse events or discontinuations, distinguishing it from current JAK inhibitors that require boxed warnings.
Enveda (search) announced positive Phase 1b results for ENV-294, a first-in-class oral therapy for moderate-to-severe atopic dermatitis (search), demonstrating rapid and deep clinical responses with an 85% mean reduction in Eczema Area and Severity Index (EASI) scores by Day 42. The open-label study enrolled nine adults with moderate-to-severe atopic dermatitis who received 800 mg of ENV-294 once daily for 28 days, followed by a 14-day observation period.
Robust Efficacy with Durable Responses
The trial demonstrated remarkable efficacy outcomes, with patients achieving a mean 68% reduction in EASI scores by Day 28, which deepened to 85% by Day 42, two weeks after treatment cessation. All patients achieved EASI-50 at Day 42, with 78% reaching EASI-75 and 56% achieving EASI-90. Additionally, 44% of patients achieved a vIGA-AD score of 0 or 1, including two patients with complete skin clearance by Day 42.
Notably, one patient with complete skin clearance was a confirmed non-responder to IL4R (search) pathway biologic therapy, suggesting potential efficacy in treatment-resistant cases. Responses were observed as early as Day 8 and continued to improve after treatment ended, indicating potential for durable disease modification.
The study also reported meaningful improvements in total itch from baseline, as measured by Peak Pruritus NRS and SCORAD, consistent with lesion improvement in patients.
Novel Mechanism of Action
ENV-294 operates as a non-degrading molecular glue, termed "LOCKTAC," that resets the cellular immune response to chronic inflammation rather than suppressing individual cytokines. According to Viswa Colluru, Ph.D., Founder and CEO of Enveda (search), "Rather than suppressing individual cytokines, it is a non-degrading molecular glue, or 'LOCKTAC,' that resets the cellular immune response to chronic inflammation."
Serum and skin biomarker data from the Phase 1b trial provided consistent, multi-modal evidence of on-target engagement and modulation of multiple disease pathways. The data support a model in which ENV-294 drives a pan-endotype treatment response by reconfiguring cellular immunity to chronic inflammation, rather than the single-axis cytokine blockade employed by current therapies.
Favorable Safety Profile
ENV-294 demonstrated a favorable safety profile with no serious or severe adverse events reported and no treatment-related adverse events or discontinuations. No clinically meaningful changes were observed in laboratory parameters, vital signs, or ECGs, and the therapy showed no safety signals typically associated with existing systemic treatments, including those linked to immunosuppression.
Dr. Leon Kircik, Clinical Professor at Mount Sinai and lead investigator, noted, "What struck me was how well patients tolerated ENV-294 with no serious or severe adverse events, no discontinuations, and a safety profile distinct from what we typically see with systemic immunosuppressants or JAK inhibitors."
Clinical Context and Expert Perspectives
Dr. Jonathan Silverberg, Professor of Dermatology at The George Washington University School of Medicine and Health Sciences, emphasized the potential significance of these results: "The atopic dermatitis (search) treatment landscape has advanced with biologics and JAK inhibitors, but no oral therapy today delivers JAK-inhibitor-like efficacy without boxed warnings and laboratory monitoring."
The biomarker profile indicates broad activity across Th2 (search), Th17 (search), and Th1 (search) pathways, which Dr. Silverberg noted is "particularly relevant in many atopic dermatitis (search) patients with mixed or non–Th2-driven disease."
Future Development Plans
Enveda (search) is advancing ENV-294 into Phase 2a trials in atopic dermatitis (search) and asthma (search), with a Phase 2b study planned for mid-2026. The company is also developing additional clinical programs in inflammatory bowel disease (search) and obesity (search), positioning ENV-294 as a potential first-in-class innovation across multiple inflammatory conditions.